Top

Published in:

01-02-2021 | Pancreatic Tumors

Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)

Authors: Andre Alabd, MD, Andrew Alabd, MD, Oloruntoba Bolaji, DO, Kavin Sugumar, MD, John Ammori, MD, Jeffrey Hardacre, MD, Jordan M. Winter, MD

Published in: Annals of Surgical Oncology | Issue 2/2021

Abstract

Background

Overall survival (OS) has increased in recent adjuvant clinical trials of pancreatic ductal adenocarcinoma (PDAC). Although oncologists have taken notice, the root causes have not been fully examined.

Methods

All phase 3 adjuvant PDAC clinical trials were screened (n = 13), and eight trials (2007–2019) that met a study requirement of having a gemcitabine monotherapy arm to serve as a uniform comparative anchor across trials were identified. Patient enrollment eligibility criteria were compared across trials and categorized as tumor- or patient-related factors. Disease-free survival (DFS) and OS in the gemcitabine-only and non-gemcitabine arms were plotted and compared over time using linear regression.

Results

In the non-gemcitabine arms, OS increased over time, but the slope did not achieve statistical significance (p = 0.0815). Interestingly, OS improved for patients receiving only gemcitabine (slope, 1.99 months; p = 0.0018), whereas DFS remained constant (p = 0.897). Carbohydrate antigen (CA) 19-9 values and pathologic profiles of tumors were only marginally different across all cohorts. Recent adjuvant trials had stricter inclusion criteria (i.e., more patients were excluded for medical reasons; linear regression, p = 0.010).

Conclusion

Survival for patients with resected PDAC has roughly doubled in phase 3 adjuvant trials during the past decade. Improved outcomes likely are attributable to improved adjuvant therapeutic regimens, but also reflect healthier patients enrolled in the more recent trials.

Available only for authorised users

Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–175. https://doi.org/10.1245/s10434-011-1900-3.CrossRefPubMed

He J, Ahuja N, Makary MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB. 2014;16:83–90. https://doi.org/10.1111/hpb.12078.CrossRefPubMed

Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2006;10:1212–23; discussion 1223–4. https://doi.org/10.1016/j.gassur.2006.08.010.

Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable pancreatic [corrected] cancer? A population-based assessment of US practices. Cancer. 2010;116:1681–90. https://doi.org/10.1002/cncr.24918.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212–36. https://doi.org/10.3322/caac.20121.CrossRefPubMed

Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. https://doi.org/10.1056/nejmoa1809775.CrossRefPubMed

Reni M, Riess H, O’Reilly E, et al. An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality-of-life outcomes. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(Suppl 4):iv126. https://doi.org/10.1093/annonc/mdz154.

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet Lond Engl. 2017;389:1011–24. https://doi.org/10.1016/s0140-6736(16)32409-6.CrossRef

10.

Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81. https://doi.org/10.1001/jama.2010.1275.CrossRefPubMed

11.

Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77. https://doi.org/10.1001/jama.297.3.267.CrossRefPubMed

12.

Sinn M, Bahra M, Liersch T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3330–7. https://doi.org/10.1200/jco.2017.72.6463.CrossRef

13.

Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15. https://doi.org/10.1038/sj.bjc.6605256.CrossRefPubMedPubMedCentral

14.

Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet Lond Engl. 2016;388:248–57. https://doi.org/10.1016/s0140-6736(16)30583-9.CrossRef

15.

Reni M, Winter J, Tortora G, et al. PD-001–analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Ann Oncol. 2019;30:iv110. https://doi.org/10.1093/annonc/mdz156.

16.

Riess H, Braverman J, Reni M, et al. Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P + GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT). Ann Oncol. 2019;30:v260–1. https://doi.org/10.1093/annonc/mdz247.012.CrossRef

17.

Tempero MA, Reni M, Riess H, et al. Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses. Ann Oncol. 2019;30:v259–60. https://doi.org/10.1093/annonc/mdz247.010.CrossRef

18.

Tempero M, Reni M, Riess H, et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab^®-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma. Oral abstract session presented at the: 2019 ASCO Annual Meeting, 2 June 2019; Chicago, IL. Retrieved 22 August 2019 at https://meetinglibrary.asco.org/record/173181/abstract.

19.

Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28:3617–22. https://doi.org/10.1200/jco.2010.28.1386.CrossRefPubMedPubMedCentral

20.

Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol. 2013;18:839–46. https://doi.org/10.1007/s10147-012-0474-9.CrossRefPubMed

21.

Thobie A, Mulliri A, Dolet N, et al. Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: a high-resolution population-based cancer registry study. Surg Oncol. 2018;27:759–66. https://doi.org/10.1016/j.suronc.2018.10.008.CrossRefPubMed

22.

van Roest MHG, van der Aa MA, van der Geest LGM, de Jong KP. The impact of socioeconomic status, surgical resection and type of hospital on survival in patients with pancreatic cancer. a population-based study in The Netherlands. PLoS ONE. 2016;11. https://doi.org/10.1371/journal.pone.0166449.

23.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. https://doi.org/10.1056/nejmoa1011923.CrossRefPubMed

24.

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. https://doi.org/10.1056/nejmoa1304369.CrossRef

25.

Cady B. Basic principles in surgical oncology. Arch Surg Chicago IL 1960. 1997;132:338–46. https://doi.org/10.1001/archsurg.1997.01430280012001.CrossRef

Title: Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)
Authors: Andre Alabd, MD
Andrew Alabd, MD
Oloruntoba Bolaji, DO
Kavin Sugumar, MD
John Ammori, MD
Jeffrey Hardacre, MD
Jordan M. Winter, MD
Publication date: 01-02-2021
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 2/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08859-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

ASO Author Reflections: Hepatocellular Carcinoma-Related Tumor Necrosis is Associated with Worse Long-Term Outcomes

Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

CD36 Expression Is Associated with Cancer Aggressiveness and Energy Source in Esophageal Squamous Cell Carcinoma

The Landmark Series: Mitigation of the Postoperative Pancreatic Fistula

Enhanced Recovery After Surgery (ERAS) in Head and Neck Oncologic Surgery: A Case-Matched Analysis of Perioperative and Pain Outcomes

Digestive Reconstruction After Pharyngolaryngectomy with Total Esophagectomy